124750-51-2 (N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑,N-(Triphenylmethyl)-5-(4-bromomethylbiphenyl-2-yl)tetrazole)

CAS号:
124750-51-2
中文名称:
N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑
英文名称:
N-(Triphenylmethyl)-5-(4-bromomethylbiphenyl-2-yl)tetrazole
分子式:
C33H25BrN4
分子量:
557.482406377792
API:

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)名称与标识符

名称

中文别名:
N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑;5-(4-溴甲基-1,1-联苯-2-基)-1-三苯甲基四唑;5-[4'-溴甲基[1,1'-二苯基]-2-基]-1-三苯甲基-1H-四氮;5-[4'-溴甲基联苯-2-基]-1-三苯甲基-1H-四氮唑;N-三苯基甲基5-(4-溴甲基二苯基-2-基) 四唑E;5-[4'-(溴甲基)-1,1'-联苯-2-基]-1-三苯基甲基-1H-四唑;5-(4’-(溴甲基)联苯-2-基)-1-三苯甲基-1H-四唑;5-(4’-溴甲基联苯-2-基)-1-三苯基甲基四氮唑;5-(4鈥?-(BROMOMETHYL)(1,1鈥?-BIPHENYL)-2-YL)-1-TRITYL-1H-TETRAAZOLE;BBTT(TTBB)四氮唑;N-(三苯基甲基)-5-(4’-溴甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4’溴-甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4’-溴甲基联苯-2-基)四氮唑(简称BBTT);N-(三苯基甲基)-5-(4′-溴甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4''''-溴甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4''-溴甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4-溴甲基联苯-2-基)四氮唑;N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(BBTT);奥美沙坦杂质;奥美沙坦酯中间体;辅酶Q0;联苯四氮唑;三苯甲基溴甲基联苯四氮唑;四氮唑;溴代三苯甲基四氮唑;5-(4'-溴甲基联苯-2-基)-1-三苯基甲基四氮唑;溴代坎地沙坦杂质;奥美沙坦酯杂质30;BBTT;N-(三苯基甲基)-5-(4’-溴甲基联苯-2-基)四氮唑(奥美沙坦中间体);
英文别名:
N-(Triphenylmethyl)-5-(4-bromomethylbiphenyl-2-yl)tetrazole;5-(4'-BROMOMETHYL-1,1'-BIPHENYL-2-YL)-1-TRIPHENYLMETHYL-1H-TETRAZOLE;5-(4'-BROMOMETHYL-BIPHENYL-2-YL)-1-TRITYL-1H-TETRAZOLE;N-(TRIPHENYLMETHYL)-5-(4'-BROMOMETHYLBIPHENYL-2-YL) TETRAZOLE;1H-Tetrazole, 5-[4'-(bromomethyl)[1,1'-biphenyl]-2-yl]-1-(triphenylmethyl)-;Trityl tetrazole bromomethyl biphenyl;5-(4'-(BROMOMETHYL)(1,1'-BIPHENYL)-2-YL)-1-TRITYL-;5-[4'-(Bromomethyl)[1,1'-Biphenyl]-1-(Triphenylmethyl)Tetrazole];N-(Triphenylmethyl)C5-(4'-Bromomethylbiphenyl-2Yl)Tetrazole;Valsartan intermediate;5-[4Bromomethyl-(1,1biphenyl)-2-yl]-1-triphenylmethyltetrazole;N-(TRIPHENYLMETHYL)-5-(4''-BROMOMETHYLBIPHENYL-2-YL-)TETRAZOLE(BBTT);(TRIPHENYLMETHYL)TETRAZOLE;5-[4'-bromomethyl-1,1'-biphenyl-2-yl]-1-trityl-1H-tetrazole;5-(4'-(BROMOMETHYL)(1,1'-BIPHENYL)-2-YL)-1-TRITYL-1H-TETRAAZOLE;n-(triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl-)terazole;5-[4’-Bromomethyl-(1,1’-biphenyl)-2-yl]-1-triphenylmethyltetrazole;5-[4'-(Bromomethyl)-1,1'-biphenyl-2-yl]-1-triphenylmethyl-1H-tetrazole;5-(4'-(Bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole;5-(4'-BROMOMETHYL-1,1-BIPHENYL-2-YL)-1-TRIPHENYLMETHYL-1H-TETRAZOLE;5-[4’-Bromomethyl-(1,1’-biphenyl)-2-yl]-1-triphenylmethyltetrazole,5-[4’-Bromomethyl-(1,1’-biphenyl)-2-yl]-1-triphenylm...;5-[4-Bromomethyl-(1,1-biphenyl)-2-yl]-1-triphenylmethyltetrazole;BBTT;IRBESARTAN BROMO IMPURITY;N-(Tm)-5-(4'-bromomethylbiphenyl-2-yl )tetrazole;N-(Triphenylmethyl)-5-(4-Bromomethylbiphenyl-2-yl-)Tetrazole;TTBB;5-[2-[4-(bromomethyl)phenyl]phenyl]-1-trityltetrazole;N-(Triphenylmethyl)-5-(4-Bromomethylbiphenyl-2-yl-)Tetrazole(Bbtt);5-[4'-(bromomethyl)[1,1'-bi-phenyl]-2-yl]-1-(triphenylmethyl) -1H-tetrazole;5-[4'-(bromomethyl)[1,1'-biphenyl]-2-yl]-1-trityl-1H-tetraazole;SCHEMBL796;5-(4'-Bromomethylbiphenyl-2-yl)-1-trityl-1H-tetrazole;N-triphenylmethyl-5-(4'-bromomethylbiphen-2-yl)tetrazole;4-bromomethyl-2'-[N-triphenylmethyl-(1H-tetrazol-5yl)]biphenyl;NS00004998;N-triphenylmethyl-5-(4'-bromomethylbiphenyl-2-yl)tetrazole;5-[4'-(Bromomethyl)-1,1'-biphenyl-2-yl]-1-trityl-1H-tetrazole;DTXSID80434768;4'-bromomethyl-2-(1-triphenylmethyltetrazol-5-yl)-biphenyl;4-bromomethyl-2'-(N-trityltetrazol-5yl)biphenyl;5-(4'-(Bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole...;5-[4'-(bromomethyl)-[1,1'-biphenyl]-2-yl]-1-(triphenylmethyl) -1H-tetrazole;N-Triphenylmethyl-5-[4'-(bromomethyl)biphenyl-2-yl]tetrazole;Q-200519;EC 603-010-9;N-triphenylmethyl 5-[4'-(bromomethyl)biphenyl-2yl]tetrazole;N-Triphenylmethyl-5-(4'-(bromomethyl)biphenyl-2-yl]tetrazole;A20648;4-bromomethyl-2'-[N-triphenylmethyl-(1H-tetrazol-5-yl)]biphenyl;5-(4'-bromomethyl biphenyl-2-yl)-1-trityl-1H-tetrazole;5-[4'-(bromomethyl)-[1,1'-biphenyl]-2-yl]-1-(triphenylmethyl)-1H-1,2,3,4-tetrazole;2'-(N-triphenylmethyltetrazol-5-yl)biphen-4-yl methyl bromide;4-Bromomethyl-2'-(N-triphenylmethy-(1H-tetrazol-5-yl))biphenyl;[[2'-(N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl] bromide;GS-3620;5-[4'-(bromomethyl)[1,1'biphenyl]-2-yl]-1-(triphenylmethyl)-1H-tetrazole;FT-0600867;[[2'-[N-(triphenylmethyl)tetrazol-5-yl]-1,1'-biphenyl-4-yl]methyl] bromide;4-[2'-(N-trityltetrazol-5-yl)phenyl]benzyl bromide;MFCD00665221;N-triphenylmethyl-5-(4'-bromomethylbiphenyl-2-yl)-tetrazole;[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl bromide;4-bromomethyl-2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl;C33H25BrN4;5-(4'-Bromomethyl-biphenyl-2-yl)-N-(triphenylmethyl)tetrazole;N-(triphenylmethyl)-5-[4'-(bromomethyl)biphenyl-2-yl]tetrazole;CS-W009602;AC-1836;N-(triphenylmethyl)-5-(4'-bromomethyl biphenyl-2-yl) tetrazole;5-[2-[4-(bromomethyl)phenyl]phenyl]-1-trityl-tetrazole;5-(4'-(bromomethyl)biphenyl-2-yl)-1-trityl-1h-tetrazole;N-(Triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl-)terazole;Trityl tetrazole bromomethyl biphenyl;5-(4'-(Bromomethyl)-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole;ZTFVTXDWDFIQEU-UHFFFAOYSA-N;5-(4'-(bromomethyl)-[1,1'-biphenyl]-2-yl]-1-(triphenylmethyl)-1H-tetrazole;AM90281;2'-(N-triphenylmethyl tetrazol-5-yl)-4-bromomethylbiphenyl;5-[4'-(bromomethyl)[1,1'-biphenyl]-2-yl]-1-(triphenylmethyl)-1H-tetrazole;AKOS000278516;4'-bromomethyl-2-(1-triphenylmethyltetrazol-5-yl)biphenyl;N-(triphenylmethyl)-5-(4'-bromomethyl biphenyl-2-yl)tetrazole;4'-bromomethyl-2-(1-triphenylmethyl-1H-tetrazol-5-yl)-biphenyl;4-Bromomethyl-2'-(1-triphenylmethyltetrazol-5-yl)biphenyl;5-[4'-(Bromomethyl)-2-biphenylyl]-1-trityl-1H-tetrazole;5-[4'-Bromomethyl-(1,1'-biphenyl)-2-yl]-1-triphenylmethyltetrazole;4-[2-(trityltetrazol-5-yl)-phenyl]benzyl bromide;124750-51-2;n-(triphenylmethyl)-5 (4'-bromomethylbiphenyl-2-yl)tetrazole;4-[2-(trityltetrazol-5-yl)phenyl]benzyl bromide;BCP12001;4-(bromomethyl)-2'-(1-triphenylmethyltetrazol-5-yl)biphenyl;B4462;[2'-(1-trityl-1H-tetrazol-5-yl)bipheyl-4-yl]methyl bromide;N-(triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl)tetrazole;N-(Triphenylmethyl)-5-(4'-bromomethylbiphenyl-2-yl-)tetrazole;4-[2-(trityltetrazol-5-yl)phenyl]benzylbromide;4'-bromomethyl-2-(1-triphenylmethyl-tetrazol-5-yl)-biphenyl;4-Bromomethyl-2'-(triphenylmethyltetrazol-5-yl)biphenyl;5-[4-(Bromomethyl)-1,1-Biphenyl-2-yl]-1-Triphenylmethyl-1H-Tetrazole;5-[4'-(bromomethyl)biphenyl-2-yl]-N-trityltetrazole;4-bromomethyl-2'-(1-triphenylmethyl-1H-tetrazol-5-yl)-biphenyl;N-triphenylmethyl-5-(4'-bromomethylbiphenyl-2-yl) tetrazole;4-bromomethyl-2'-(N-trityltetrazol-5-yl)biphenyl;4-[2'-(N-trityltetrazol-5-yl)phenyl]benzylbromide;

标识符

MDL:
MFCD09838964
InChIKey:
ZTFVTXDWDFIQEU-UHFFFAOYSA-N
Inchi:
1S/C33H25BrN4/c34-24-25-20-22-26(23-21-25)30-18-10-11-19-31(30)32-35-36-37-38(32)33(27-12-4-1-5-13-27,28-14-6-2-7-15-28)29-16-8-3-9-17-29/h1-23H,24H2
SMILES:
BrCC1C=CC(=CC=1)C1=CC=CC=C1C1=NN=NN1C(C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)物化性质

实验特性

  • LogP : 7.74220
  • PSA : 43.60000
  • 折射率 : 1.66
  • 沸点 : 718.4°C at 760 mmHg
  • 熔点 : 135-138°C
  • 蒸气压 : 0.0±2.3 mmHg at 25°C
  • 闪点 : 388.3±35.7 °C
  • 颜色与性状 : 灰白色固体
  • 稳定性 : Moisture Sensitive
  • 密度 : 1.3±0.1 g/cm3

计算特性

  • 精确分子量 : 556.12600
  • 氢键供体数量 : 0
  • 氢键受体数量 : 4
  • 可旋转化学键数量 : 7
  • 同位素质量 : 556.126
  • 重原子数量 : 38
  • 复杂度 : 660
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 8.2
  • 拓扑分子极性表面积 : 43.6A^2

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)安全信息

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)生产方法和用途

方法:
HPLC
用途:
用作药物依贝沙坦中间体

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)推荐厂家 更多厂家(123)

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)谱图信息

1H NMR300 MHzDMSO
1H NMR
13C NMR
13C NMR

N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑(124750-51-2)参考资料

Reaxys RN:
PubChem CID: